Peter Buttrick
Concepts (571)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardium | 56 | 2026 | 948 | 3.480 |
Why?
| | Heart Ventricles | 20 | 2023 | 762 | 2.040 |
Why?
| | Heart Failure | 22 | 2026 | 2329 | 1.840 |
Why?
| | Myocardial Contraction | 23 | 2011 | 292 | 1.830 |
Why?
| | Protein Kinase C | 20 | 2014 | 250 | 1.810 |
Why?
| | Cardiomegaly | 21 | 2013 | 175 | 1.670 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 248 | 1.510 |
Why?
| | Myocytes, Cardiac | 15 | 2026 | 544 | 1.410 |
Why?
| | Troponin I | 10 | 2013 | 74 | 1.170 |
Why?
| | Isoenzymes | 18 | 2002 | 294 | 1.130 |
Why?
| | Heart | 22 | 2022 | 626 | 1.020 |
Why?
| | Actin Cytoskeleton | 7 | 2011 | 97 | 0.870 |
Why?
| | Ventricular Remodeling | 10 | 2026 | 283 | 0.840 |
Why?
| | Heart-Assist Devices | 4 | 2026 | 572 | 0.820 |
Why?
| | Ventricular Function, Right | 6 | 2023 | 300 | 0.810 |
Why?
| | Cardiomyopathy, Dilated | 7 | 2025 | 357 | 0.800 |
Why?
| | Muscle Proteins | 5 | 2025 | 242 | 0.800 |
Why?
| | Myosins | 18 | 2018 | 131 | 0.750 |
Why?
| | Ventricular Function, Left | 6 | 2025 | 541 | 0.690 |
Why?
| | Phosphorylation | 19 | 2016 | 1724 | 0.690 |
Why?
| | Rats | 51 | 2026 | 5586 | 0.610 |
Why?
| | Protein Kinase C-epsilon | 9 | 2007 | 23 | 0.610 |
Why?
| | Hypertension, Pulmonary | 8 | 2023 | 1957 | 0.610 |
Why?
| | Myosin Light Chains | 4 | 2013 | 29 | 0.590 |
Why?
| | Stroke Volume | 10 | 2025 | 652 | 0.590 |
Why?
| | Scientific Misconduct | 1 | 2019 | 8 | 0.590 |
Why?
| | Carrier Proteins | 5 | 2022 | 728 | 0.580 |
Why?
| | Sarcomeres | 7 | 2021 | 100 | 0.550 |
Why?
| | Physical Conditioning, Animal | 8 | 2006 | 243 | 0.540 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 5 | 2011 | 125 | 0.540 |
Why?
| | Myocardial Infarction | 9 | 2013 | 1215 | 0.540 |
Why?
| | Neprilysin | 1 | 2018 | 47 | 0.520 |
Why?
| | Animals | 89 | 2026 | 38107 | 0.510 |
Why?
| | Editorial Policies | 1 | 2017 | 46 | 0.470 |
Why?
| | Gene Expression Regulation | 9 | 2019 | 2599 | 0.460 |
Why?
| | Calcium | 11 | 2011 | 1181 | 0.460 |
Why?
| | Cardiac Myosins | 2 | 2013 | 34 | 0.460 |
Why?
| | Rats, Wistar | 17 | 2006 | 451 | 0.450 |
Why?
| | Adrenergic beta-Agonists | 5 | 2002 | 91 | 0.450 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 286 | 0.440 |
Why?
| | Histone Deacetylases | 2 | 2013 | 208 | 0.420 |
Why?
| | Periodicals as Topic | 1 | 2017 | 214 | 0.410 |
Why?
| | Apoptosis | 5 | 2002 | 2439 | 0.400 |
Why?
| | Serine | 3 | 2013 | 142 | 0.400 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1064 | 0.400 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 6 | 2021 | 299 | 0.390 |
Why?
| | Valproic Acid | 1 | 2013 | 45 | 0.380 |
Why?
| | Aortic Valve Stenosis | 2 | 2013 | 255 | 0.380 |
Why?
| | Recovery of Function | 4 | 2026 | 725 | 0.380 |
Why?
| | Hydroxamic Acids | 1 | 2013 | 96 | 0.370 |
Why?
| | Ventricular Dysfunction, Left | 5 | 2023 | 391 | 0.360 |
Why?
| | Mitogen-Activated Protein Kinases | 3 | 2002 | 288 | 0.360 |
Why?
| | Gene Expression | 14 | 2017 | 1463 | 0.350 |
Why?
| | Alternative Splicing | 2 | 2026 | 253 | 0.350 |
Why?
| | Isoproterenol | 6 | 2004 | 96 | 0.350 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2025 | 253 | 0.320 |
Why?
| | Models, Biological | 3 | 2021 | 1761 | 0.320 |
Why?
| | RNA, Messenger | 15 | 2017 | 2791 | 0.310 |
Why?
| | Heart Rate | 9 | 2025 | 846 | 0.310 |
Why?
| | Dobutamine | 5 | 2005 | 24 | 0.290 |
Why?
| | Induced Pluripotent Stem Cells | 3 | 2021 | 269 | 0.290 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2011 | 58 | 0.290 |
Why?
| | Phenotype | 3 | 2025 | 3206 | 0.280 |
Why?
| | Mice | 27 | 2022 | 18297 | 0.280 |
Why?
| | Cattle | 6 | 2023 | 940 | 0.270 |
Why?
| | Angiotensin Receptor Antagonists | 3 | 1997 | 115 | 0.270 |
Why?
| | Phosphoserine | 2 | 2007 | 25 | 0.270 |
Why?
| | Humans | 54 | 2026 | 146342 | 0.260 |
Why?
| | Catecholamines | 5 | 2022 | 88 | 0.260 |
Why?
| | Hypertrophy, Right Ventricular | 3 | 2023 | 151 | 0.260 |
Why?
| | Disease Models, Animal | 11 | 2023 | 4580 | 0.250 |
Why?
| | Protein Processing, Post-Translational | 5 | 2016 | 487 | 0.250 |
Why?
| | Enzyme Inhibitors | 6 | 2002 | 823 | 0.250 |
Why?
| | Muscle Strength | 1 | 2010 | 340 | 0.250 |
Why?
| | Tissue and Organ Procurement | 1 | 2010 | 305 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 228 | 0.250 |
Why?
| | Pharmacogenetics | 1 | 2008 | 176 | 0.240 |
Why?
| | Biophysics | 1 | 2007 | 75 | 0.240 |
Why?
| | NAD | 1 | 2007 | 80 | 0.240 |
Why?
| | Hypoxia-Inducible Factor 1 | 2 | 2006 | 69 | 0.240 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2006 | 76 | 0.240 |
Why?
| | Cytosol | 1 | 2007 | 215 | 0.230 |
Why?
| | Glycolysis | 2 | 2012 | 342 | 0.230 |
Why?
| | Mice, Transgenic | 13 | 2018 | 2134 | 0.230 |
Why?
| | Mitochondria, Heart | 1 | 2007 | 107 | 0.230 |
Why?
| | Transforming Growth Factor beta | 2 | 2020 | 467 | 0.230 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 612 | 0.220 |
Why?
| | Hypertension | 5 | 2007 | 1272 | 0.220 |
Why?
| | Signal Transduction | 10 | 2021 | 5246 | 0.220 |
Why?
| | Models, Animal | 1 | 2007 | 387 | 0.220 |
Why?
| | Hypertension, Renovascular | 3 | 1994 | 15 | 0.220 |
Why?
| | Myosin Heavy Chains | 3 | 2004 | 177 | 0.210 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 307 | 0.210 |
Why?
| | Renin-Angiotensin System | 2 | 1996 | 80 | 0.210 |
Why?
| | Calcineurin | 2 | 2002 | 105 | 0.210 |
Why?
| | Male | 40 | 2026 | 73396 | 0.210 |
Why?
| | Fibroblasts | 4 | 2020 | 1034 | 0.200 |
Why?
| | Endothelium, Vascular | 3 | 2019 | 952 | 0.200 |
Why?
| | Angiotensin II | 2 | 2001 | 102 | 0.190 |
Why?
| | GATA4 Transcription Factor | 2 | 2020 | 19 | 0.190 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 199 | 0.190 |
Why?
| | Gene Transfer Techniques | 3 | 2000 | 185 | 0.190 |
Why?
| | Female | 50 | 2026 | 79499 | 0.190 |
Why?
| | Chronic Disease | 2 | 2020 | 1827 | 0.190 |
Why?
| | Collagen | 3 | 2016 | 460 | 0.180 |
Why?
| | Thromboxane A2 | 2 | 2002 | 9 | 0.180 |
Why?
| | Cardiovascular Diseases | 3 | 2007 | 2219 | 0.180 |
Why?
| | Cardiac Output, Low | 1 | 2002 | 53 | 0.180 |
Why?
| | Hemodynamics | 9 | 2011 | 1114 | 0.180 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2001 | 27 | 0.170 |
Why?
| | Dilatation, Pathologic | 1 | 2001 | 60 | 0.170 |
Why?
| | Proto-Oncogene Proteins | 2 | 2002 | 616 | 0.170 |
Why?
| | Rats, Inbred Strains | 14 | 1992 | 316 | 0.170 |
Why?
| | Heart Diseases | 2 | 2019 | 343 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2002 | 97 | 0.170 |
Why?
| | Calcium Signaling | 3 | 2011 | 246 | 0.160 |
Why?
| | Genetic Therapy | 3 | 2000 | 303 | 0.160 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2021 | 902 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2004 | 198 | 0.160 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 974 | 0.160 |
Why?
| | Organ Size | 12 | 2001 | 465 | 0.160 |
Why?
| | Brachial Artery | 1 | 2002 | 207 | 0.160 |
Why?
| | Cyclosporine | 1 | 2001 | 256 | 0.160 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 64 | 0.160 |
Why?
| | Blood Pressure | 11 | 2012 | 1765 | 0.150 |
Why?
| | Biomedical Research | 1 | 2007 | 729 | 0.150 |
Why?
| | Molecular Sequence Data | 8 | 2012 | 2838 | 0.150 |
Why?
| | RNA, Long Noncoding | 1 | 2022 | 174 | 0.150 |
Why?
| | Adaptation, Physiological | 4 | 2012 | 568 | 0.150 |
Why?
| | Cardiotonic Agents | 3 | 2005 | 96 | 0.150 |
Why?
| | Tetrazoles | 2 | 1997 | 50 | 0.150 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2021 | 144 | 0.150 |
Why?
| | Cell Dedifferentiation | 1 | 2019 | 31 | 0.150 |
Why?
| | Cells, Cultured | 13 | 2021 | 4118 | 0.150 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2002 | 292 | 0.150 |
Why?
| | Animals, Newborn | 5 | 2011 | 888 | 0.150 |
Why?
| | Phototherapy | 1 | 2019 | 49 | 0.150 |
Why?
| | Cocaine | 2 | 1991 | 162 | 0.150 |
Why?
| | Lysosomal-Associated Membrane Protein 2 | 1 | 2018 | 32 | 0.140 |
Why?
| | Autophagosomes | 1 | 2018 | 20 | 0.140 |
Why?
| | Body Weight | 10 | 2001 | 968 | 0.140 |
Why?
| | Glycogen Storage Disease Type IIb | 1 | 2018 | 27 | 0.140 |
Why?
| | Circadian Clocks | 1 | 2019 | 59 | 0.140 |
Why?
| | Membrane Fusion | 1 | 2018 | 40 | 0.140 |
Why?
| | In Vitro Techniques | 8 | 2011 | 1041 | 0.140 |
Why?
| | Imidazoles | 2 | 1997 | 245 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 371 | 0.140 |
Why?
| | Lysosomes | 1 | 2018 | 134 | 0.140 |
Why?
| | Amphiregulin | 1 | 2018 | 27 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2002 | 384 | 0.130 |
Why?
| | Transfection | 4 | 2002 | 916 | 0.130 |
Why?
| | Systole | 3 | 2005 | 179 | 0.130 |
Why?
| | Adenosine Triphosphatases | 5 | 2005 | 158 | 0.130 |
Why?
| | Echocardiography | 3 | 2009 | 645 | 0.130 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 6 | 0.130 |
Why?
| | Filamins | 1 | 2018 | 28 | 0.130 |
Why?
| | In Situ Nick-End Labeling | 3 | 2002 | 120 | 0.130 |
Why?
| | Physical Exertion | 3 | 1988 | 204 | 0.130 |
Why?
| | Enzyme Activation | 4 | 2002 | 759 | 0.130 |
Why?
| | Actomyosin | 1 | 1997 | 20 | 0.130 |
Why?
| | Period Circadian Proteins | 2 | 2019 | 33 | 0.130 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2018 | 140 | 0.120 |
Why?
| | Protein Kinase C beta | 6 | 2008 | 21 | 0.120 |
Why?
| | Middle Aged | 13 | 2026 | 36619 | 0.120 |
Why?
| | Aging | 5 | 2008 | 1996 | 0.120 |
Why?
| | Coronary Circulation | 4 | 2004 | 134 | 0.120 |
Why?
| | Angiotensin I | 1 | 1996 | 7 | 0.120 |
Why?
| | Myofibrils | 2 | 2021 | 55 | 0.120 |
Why?
| | Activities of Daily Living | 1 | 2020 | 442 | 0.120 |
Why?
| | Patient Participation | 1 | 2020 | 457 | 0.120 |
Why?
| | Mice, Inbred C57BL | 8 | 2020 | 6034 | 0.110 |
Why?
| | Cellular Reprogramming Techniques | 1 | 2015 | 9 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 6 | 2026 | 2537 | 0.110 |
Why?
| | Sex Characteristics | 3 | 2006 | 801 | 0.110 |
Why?
| | Amino Acid Substitution | 2 | 2007 | 297 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1996 | 193 | 0.110 |
Why?
| | Hypoxia | 4 | 2023 | 1211 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2002 | 751 | 0.110 |
Why?
| | Ultrasonography | 2 | 2012 | 788 | 0.110 |
Why?
| | rho-Associated Kinases | 1 | 2015 | 77 | 0.110 |
Why?
| | Blotting, Western | 2 | 2015 | 1177 | 0.110 |
Why?
| | Time Factors | 8 | 2009 | 7109 | 0.110 |
Why?
| | Cellular Reprogramming | 1 | 2015 | 98 | 0.110 |
Why?
| | Coronary Vessels | 2 | 1987 | 245 | 0.100 |
Why?
| | Interleukin-18 | 1 | 2016 | 234 | 0.100 |
Why?
| | Atrial Natriuretic Factor | 2 | 2007 | 54 | 0.100 |
Why?
| | Tetracycline | 1 | 1994 | 11 | 0.100 |
Why?
| | Heart Transplantation | 4 | 2011 | 682 | 0.100 |
Why?
| | Transcription, Genetic | 3 | 2019 | 1432 | 0.100 |
Why?
| | Amino Acid Sequence | 4 | 2012 | 2092 | 0.100 |
Why?
| | Renin | 1 | 1993 | 33 | 0.100 |
Why?
| | Cardiac Output | 3 | 2012 | 176 | 0.100 |
Why?
| | Protein Phosphatase 1 | 1 | 2013 | 32 | 0.100 |
Why?
| | Sodium, Dietary | 1 | 1993 | 43 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2021 | 1982 | 0.090 |
Why?
| | Immunohistochemistry | 4 | 2018 | 1712 | 0.090 |
Why?
| | Protein Phosphatase 2 | 1 | 2013 | 41 | 0.090 |
Why?
| | Cell Line | 6 | 2021 | 2814 | 0.090 |
Why?
| | Antibodies | 2 | 2013 | 400 | 0.090 |
Why?
| | Protein Disulfide-Isomerases | 1 | 2012 | 12 | 0.090 |
Why?
| | Contractile Proteins | 5 | 1996 | 13 | 0.090 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2005 | 216 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 1996 | 519 | 0.090 |
Why?
| | Ventricular Function | 2 | 1991 | 53 | 0.090 |
Why?
| | Receptor, Adenosine A2B | 1 | 2012 | 65 | 0.090 |
Why?
| | Kinetics | 4 | 2011 | 1553 | 0.090 |
Why?
| | Substance-Related Disorders | 2 | 1991 | 1100 | 0.090 |
Why?
| | Excitation Contraction Coupling | 1 | 2011 | 12 | 0.080 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 9 | 0.080 |
Why?
| | Ventricular Pressure | 1 | 2011 | 52 | 0.080 |
Why?
| | Hyperbaric Oxygenation | 1 | 2011 | 39 | 0.080 |
Why?
| | Aorta | 2 | 2007 | 440 | 0.080 |
Why?
| | Desmin | 1 | 2010 | 22 | 0.080 |
Why?
| | Ventricular Fibrillation | 1 | 1991 | 63 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1408 | 0.080 |
Why?
| | Aged | 10 | 2026 | 26432 | 0.080 |
Why?
| | Disease Progression | 3 | 2009 | 2867 | 0.080 |
Why?
| | Peptide Fragments | 2 | 2007 | 693 | 0.080 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 84 | 0.080 |
Why?
| | Epoprostenol | 3 | 1986 | 132 | 0.080 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2010 | 82 | 0.080 |
Why?
| | Chest Pain | 1 | 1990 | 100 | 0.080 |
Why?
| | Cyclic AMP | 3 | 2008 | 208 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 219 | 0.080 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 109 | 0.080 |
Why?
| | Promoter Regions, Genetic | 6 | 1994 | 1242 | 0.080 |
Why?
| | Cardiovascular Physiological Phenomena | 2 | 2006 | 48 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 156 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2002 | 441 | 0.070 |
Why?
| | Biopsy | 1 | 2013 | 1075 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2002 | 610 | 0.070 |
Why?
| | Blotting, Northern | 2 | 2001 | 197 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2012 | 449 | 0.070 |
Why?
| | MicroRNAs | 2 | 2015 | 699 | 0.070 |
Why?
| | Platelet Aggregation | 3 | 1986 | 99 | 0.070 |
Why?
| | Energy Metabolism | 3 | 2007 | 930 | 0.070 |
Why?
| | Sex Factors | 2 | 2013 | 2107 | 0.070 |
Why?
| | Prosthesis Design | 1 | 2011 | 358 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 3125 | 0.070 |
Why?
| | Toxicogenetics | 1 | 2008 | 6 | 0.070 |
Why?
| | Cell Hypoxia | 2 | 2019 | 249 | 0.070 |
Why?
| | Biomarkers, Pharmacological | 1 | 2008 | 26 | 0.070 |
Why?
| | Digoxin | 1 | 2008 | 27 | 0.070 |
Why?
| | Biological Transport | 2 | 2002 | 424 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2010 | 588 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 997 | 0.070 |
Why?
| | Gene Expression Regulation, Enzymologic | 4 | 2002 | 266 | 0.070 |
Why?
| | Mutation | 2 | 2018 | 4093 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2007 | 627 | 0.070 |
Why?
| | Embryo, Mammalian | 2 | 2020 | 230 | 0.070 |
Why?
| | Adult | 11 | 2020 | 41087 | 0.060 |
Why?
| | Arrhythmias, Cardiac | 2 | 2022 | 358 | 0.060 |
Why?
| | Consensus Sequence | 1 | 2007 | 73 | 0.060 |
Why?
| | Base Sequence | 5 | 1994 | 2123 | 0.060 |
Why?
| | RNA | 2 | 2006 | 926 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2001 | 2022 | 0.060 |
Why?
| | Protein Conformation | 1 | 2010 | 916 | 0.060 |
Why?
| | Biophysical Phenomena | 1 | 2007 | 67 | 0.060 |
Why?
| | Ligation | 1 | 2007 | 88 | 0.060 |
Why?
| | Clinical Medicine | 1 | 2007 | 26 | 0.060 |
Why?
| | Pregnancy, Animal | 1 | 1987 | 51 | 0.060 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2007 | 49 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 576 | 0.060 |
Why?
| | Heat Shock Transcription Factors | 1 | 2006 | 22 | 0.060 |
Why?
| | Thyroid Hormones | 3 | 1993 | 69 | 0.060 |
Why?
| | Chloramphenicol O-Acetyltransferase | 4 | 1994 | 33 | 0.060 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2006 | 30 | 0.060 |
Why?
| | Nitroimidazoles | 1 | 2006 | 16 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2007 | 1075 | 0.060 |
Why?
| | Fibrosis | 2 | 2015 | 568 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 147 | 0.060 |
Why?
| | Butyrates | 1 | 2007 | 65 | 0.060 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 441 | 0.060 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2006 | 72 | 0.060 |
Why?
| | DNA-Binding Proteins | 2 | 2006 | 1468 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 2006 | 140 | 0.060 |
Why?
| | Heart Atria | 1 | 1986 | 139 | 0.060 |
Why?
| | Swimming | 5 | 1990 | 54 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2013 | 3647 | 0.050 |
Why?
| | Age Factors | 3 | 2008 | 3347 | 0.050 |
Why?
| | Transcription Factors | 2 | 2006 | 1730 | 0.050 |
Why?
| | Cloning, Molecular | 3 | 1997 | 526 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2012 | 17438 | 0.050 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 40 | 0.050 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 326 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2012 | 3017 | 0.050 |
Why?
| | Mitochondrial Proteins | 1 | 2007 | 263 | 0.050 |
Why?
| | Phenylephrine | 2 | 2021 | 74 | 0.050 |
Why?
| | Enzyme Induction | 1 | 2004 | 87 | 0.050 |
Why?
| | Osteopontin | 1 | 2004 | 37 | 0.050 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 248 | 0.050 |
Why?
| | Protein Kinase C-delta | 2 | 2002 | 45 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2012 | 2502 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 149 | 0.050 |
Why?
| | Sialoglycoproteins | 1 | 2004 | 157 | 0.050 |
Why?
| | Ventricular Myosins | 1 | 2004 | 38 | 0.050 |
Why?
| | Drug Resistance | 1 | 2004 | 145 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 165 | 0.050 |
Why?
| | Up-Regulation | 2 | 2007 | 841 | 0.050 |
Why?
| | Rats, Inbred F344 | 4 | 1997 | 266 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2004 | 663 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2921 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2025 | 11821 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2081 | 0.050 |
Why?
| | Calcium-Transporting ATPases | 3 | 1993 | 33 | 0.050 |
Why?
| | Mutagenesis | 1 | 2004 | 196 | 0.050 |
Why?
| | Anticoagulants | 1 | 2008 | 746 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2002 | 19 | 0.050 |
Why?
| | Mannitol | 1 | 2002 | 42 | 0.040 |
Why?
| | Exercise Therapy | 1 | 1987 | 488 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 2002 | 165 | 0.040 |
Why?
| | Chromones | 1 | 2002 | 43 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 66 | 0.040 |
Why?
| | Massachusetts | 1 | 2022 | 178 | 0.040 |
Why?
| | Hydroxyproline | 1 | 2001 | 18 | 0.040 |
Why?
| | Pulsatile Flow | 1 | 2002 | 62 | 0.040 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 121 | 0.040 |
Why?
| | Androstadienes | 1 | 2002 | 77 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2002 | 150 | 0.040 |
Why?
| | Muscles | 3 | 1994 | 330 | 0.040 |
Why?
| | Lac Operon | 1 | 2001 | 42 | 0.040 |
Why?
| | Hypertrophy | 1 | 2001 | 127 | 0.040 |
Why?
| | Proline | 1 | 2001 | 79 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 334 | 0.040 |
Why?
| | beta-Galactosidase | 1 | 2001 | 73 | 0.040 |
Why?
| | Models, Chemical | 1 | 2002 | 252 | 0.040 |
Why?
| | Immunoblotting | 1 | 2001 | 294 | 0.040 |
Why?
| | Flavonoids | 1 | 2001 | 85 | 0.040 |
Why?
| | Morpholines | 1 | 2002 | 130 | 0.040 |
Why?
| | Glucose | 2 | 2007 | 1053 | 0.040 |
Why?
| | Substrate Specificity | 1 | 2002 | 389 | 0.040 |
Why?
| | Calcium Channels, L-Type | 1 | 2002 | 117 | 0.040 |
Why?
| | United States | 3 | 2022 | 16136 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 391 | 0.040 |
Why?
| | Sarcoplasmic Reticulum | 2 | 1993 | 37 | 0.040 |
Why?
| | American Heart Association | 1 | 2022 | 364 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 161 | 0.040 |
Why?
| | Protein Kinases | 1 | 2002 | 311 | 0.040 |
Why?
| | Cardiac Pacing, Artificial | 3 | 1998 | 83 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 33 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 2240 | 0.040 |
Why?
| | Protein Transport | 1 | 2001 | 443 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2070 | 0.040 |
Why?
| | Carotid Arteries | 1 | 2001 | 206 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 440 | 0.040 |
Why?
| | MAP Kinase Kinase Kinase 1 | 1 | 1999 | 19 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 457 | 0.040 |
Why?
| | Immediate-Early Proteins | 1 | 1999 | 46 | 0.040 |
Why?
| | Organ Culture Techniques | 2 | 2007 | 150 | 0.040 |
Why?
| | R-SNARE Proteins | 1 | 2018 | 18 | 0.040 |
Why?
| | Qa-SNARE Proteins | 1 | 2018 | 18 | 0.040 |
Why?
| | Action Potentials | 2 | 2015 | 500 | 0.040 |
Why?
| | Autophagy-Related Proteins | 1 | 2018 | 46 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2018 | 46 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2002 | 429 | 0.030 |
Why?
| | Biomechanical Phenomena | 2 | 1996 | 874 | 0.030 |
Why?
| | Cell Membrane | 1 | 2002 | 701 | 0.030 |
Why?
| | Tachycardia | 1 | 1998 | 58 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 122 | 0.030 |
Why?
| | Hypertension, Renal | 2 | 1989 | 15 | 0.030 |
Why?
| | Cell Survival | 1 | 2001 | 1105 | 0.030 |
Why?
| | Blood Platelets | 3 | 1986 | 382 | 0.030 |
Why?
| | Streptozocin | 1 | 1997 | 22 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2018 | 117 | 0.030 |
Why?
| | Prazosin | 1 | 1997 | 25 | 0.030 |
Why?
| | Death, Sudden | 1 | 1997 | 26 | 0.030 |
Why?
| | Adrenergic alpha-Agonists | 1 | 1997 | 28 | 0.030 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1998 | 124 | 0.030 |
Why?
| | Research Design | 2 | 2022 | 1143 | 0.030 |
Why?
| | Epinephrine | 3 | 1988 | 160 | 0.030 |
Why?
| | Electrocardiography | 2 | 1991 | 667 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.030 |
Why?
| | Fatty Acids | 1 | 2021 | 460 | 0.030 |
Why?
| | Threonine | 1 | 1997 | 43 | 0.030 |
Why?
| | Models, Molecular | 1 | 2002 | 1574 | 0.030 |
Why?
| | Protein Biosynthesis | 2 | 1997 | 449 | 0.030 |
Why?
| | Integrases | 1 | 2018 | 117 | 0.030 |
Why?
| | Diastole | 2 | 1988 | 147 | 0.030 |
Why?
| | Adenosine Triphosphate | 3 | 2011 | 494 | 0.030 |
Why?
| | Regional Blood Flow | 2 | 2012 | 507 | 0.030 |
Why?
| | Europe | 1 | 2018 | 421 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 410 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2023 | 876 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2018 | 447 | 0.030 |
Why?
| | Biomarkers | 2 | 2013 | 4340 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1997 | 371 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 232 | 0.030 |
Why?
| | Alanine | 1 | 1997 | 171 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1203 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 1993 | 90 | 0.030 |
Why?
| | Peptides | 1 | 2001 | 992 | 0.030 |
Why?
| | MEF2 Transcription Factors | 1 | 2015 | 51 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2016 | 85 | 0.030 |
Why?
| | Dogs | 1 | 1997 | 517 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 633 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 725 | 0.030 |
Why?
| | Creatine Kinase | 2 | 1997 | 70 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 597 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2015 | 139 | 0.030 |
Why?
| | Histones | 1 | 2020 | 670 | 0.030 |
Why?
| | Phosphofructokinase-1 | 1 | 2014 | 6 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 174 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 106 | 0.030 |
Why?
| | Oligonucleotide Probes | 1 | 1994 | 48 | 0.030 |
Why?
| | Glucose Transporter Type 4 | 1 | 2014 | 39 | 0.030 |
Why?
| | Luciferases | 2 | 1992 | 153 | 0.030 |
Why?
| | Antibody Specificity | 2 | 2013 | 181 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 334 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2014 | 42 | 0.030 |
Why?
| | Troponin | 1 | 1994 | 50 | 0.030 |
Why?
| | Succinate Dehydrogenase | 1 | 1994 | 65 | 0.030 |
Why?
| | Cytochalasin B | 1 | 1974 | 8 | 0.030 |
Why?
| | Oxygen Consumption | 3 | 1997 | 721 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 1974 | 41 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1331 | 0.030 |
Why?
| | Adenoviridae | 1 | 1994 | 197 | 0.020 |
Why?
| | Connexin 43 | 1 | 1994 | 37 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1792 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1361 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2014 | 192 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1763 | 0.020 |
Why?
| | Norepinephrine | 3 | 1992 | 201 | 0.020 |
Why?
| | Thyroxine | 1 | 1994 | 67 | 0.020 |
Why?
| | Cytomegalovirus | 1 | 1993 | 172 | 0.020 |
Why?
| | Immunodominant Epitopes | 1 | 2012 | 27 | 0.020 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2012 | 32 | 0.020 |
Why?
| | Avian Sarcoma Viruses | 1 | 1992 | 4 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 1994 | 369 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2012 | 56 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 545 | 0.020 |
Why?
| | Genes, Viral | 1 | 1992 | 88 | 0.020 |
Why?
| | Erythrocytes | 2 | 1977 | 750 | 0.020 |
Why?
| | Rabbits | 3 | 1993 | 651 | 0.020 |
Why?
| | src-Family Kinases | 1 | 2012 | 93 | 0.020 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 1992 | 116 | 0.020 |
Why?
| | Cardioplegic Solutions | 1 | 2011 | 3 | 0.020 |
Why?
| | Phosphorus Radioisotopes | 1 | 2011 | 24 | 0.020 |
Why?
| | Buffers | 1 | 2011 | 56 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1354 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 155 | 0.020 |
Why?
| | Swine | 1 | 2013 | 821 | 0.020 |
Why?
| | Antigen Presentation | 1 | 2012 | 209 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 226 | 0.020 |
Why?
| | New York City | 1 | 1990 | 89 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2005 | 2623 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1991 | 165 | 0.020 |
Why?
| | Perfusion | 2 | 1997 | 255 | 0.020 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2012 | 207 | 0.020 |
Why?
| | Education, Medical, Continuing | 1 | 1991 | 130 | 0.020 |
Why?
| | Growth Hormone | 1 | 1990 | 91 | 0.020 |
Why?
| | Women's Health | 1 | 1992 | 317 | 0.020 |
Why?
| | Muscle, Skeletal | 2 | 1997 | 1818 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 268 | 0.020 |
Why?
| | Gonadal Steroid Hormones | 1 | 1990 | 143 | 0.020 |
Why?
| | Genes | 1 | 1989 | 215 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 1994 | 2012 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2488 | 0.020 |
Why?
| | Phosphocreatine | 2 | 1999 | 44 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2113 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 532 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 1988 | 170 | 0.020 |
Why?
| | Cell Size | 1 | 2008 | 95 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 610 | 0.020 |
Why?
| | DNA | 2 | 1991 | 1421 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2007 | 40 | 0.020 |
Why?
| | Citric Acid Cycle | 1 | 2007 | 58 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2007 | 59 | 0.020 |
Why?
| | Mitral Valve Stenosis | 1 | 1986 | 20 | 0.020 |
Why?
| | Peptide Hormones | 1 | 2006 | 11 | 0.010 |
Why?
| | Risk Factors | 2 | 1991 | 10921 | 0.010 |
Why?
| | Mitral Valve Insufficiency | 1 | 1986 | 69 | 0.010 |
Why?
| | Phentolamine | 1 | 1985 | 19 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3416 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2007 | 497 | 0.010 |
Why?
| | Prospective Studies | 1 | 2018 | 8123 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 1985 | 75 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8391 | 0.010 |
Why?
| | Cardiovascular System | 1 | 2006 | 137 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1512 | 0.010 |
Why?
| | Actins | 1 | 1987 | 422 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1986 | 365 | 0.010 |
Why?
| | Rats, Inbred BN | 1 | 2004 | 56 | 0.010 |
Why?
| | Rats, Inbred Lew | 1 | 2004 | 105 | 0.010 |
Why?
| | Homeostasis | 1 | 2008 | 646 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 2 | 1999 | 534 | 0.010 |
Why?
| | Motor Activity | 1 | 1988 | 704 | 0.010 |
Why?
| | Algorithms | 1 | 2011 | 1849 | 0.010 |
Why?
| | Phenanthridines | 1 | 2002 | 7 | 0.010 |
Why?
| | Benzophenanthridines | 1 | 2002 | 10 | 0.010 |
Why?
| | Prognosis | 1 | 1991 | 4351 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2002 | 13 | 0.010 |
Why?
| | Mesylates | 1 | 2002 | 7 | 0.010 |
Why?
| | Detergents | 1 | 2002 | 42 | 0.010 |
Why?
| | Alkaloids | 1 | 2002 | 28 | 0.010 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2002 | 128 | 0.010 |
Why?
| | Second Messenger Systems | 1 | 2002 | 31 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2006 | 536 | 0.010 |
Why?
| | Aspirin | 1 | 1985 | 405 | 0.010 |
Why?
| | Membrane Potentials | 1 | 2002 | 278 | 0.010 |
Why?
| | Fetus | 2 | 1997 | 800 | 0.010 |
Why?
| | Pyrroles | 1 | 2002 | 222 | 0.010 |
Why?
| | Tamoxifen | 1 | 1981 | 193 | 0.010 |
Why?
| | Phosphates | 1 | 2001 | 175 | 0.010 |
Why?
| | Exercise | 1 | 1992 | 2213 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 2001 | 221 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1999 | 46 | 0.010 |
Why?
| | Early Growth Response Protein 1 | 1 | 1999 | 32 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1309 | 0.010 |
Why?
| | Deoxyuracil Nucleotides | 1 | 1998 | 4 | 0.010 |
Why?
| | DNA Ligases | 1 | 1998 | 7 | 0.010 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 165 | 0.010 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 1998 | 12 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 2 | 1989 | 175 | 0.010 |
Why?
| | Constriction | 1 | 1998 | 45 | 0.010 |
Why?
| | Estrogens | 2 | 1992 | 364 | 0.010 |
Why?
| | Aorta, Abdominal | 1 | 1998 | 51 | 0.010 |
Why?
| | Erythrocyte Membrane | 1 | 1977 | 55 | 0.010 |
Why?
| | Carbohydrates | 1 | 1977 | 66 | 0.010 |
Why?
| | Protein Kinase C-alpha | 1 | 1997 | 37 | 0.010 |
Why?
| | beta-Thromboglobulin | 2 | 1986 | 3 | 0.010 |
Why?
| | Thromboxane B2 | 2 | 1986 | 23 | 0.010 |
Why?
| | Running | 2 | 1988 | 235 | 0.010 |
Why?
| | RNA, Transfer, Leu | 1 | 1994 | 7 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3926 | 0.010 |
Why?
| | Melanoma | 1 | 1981 | 765 | 0.010 |
Why?
| | Immune Adherence Reaction | 1 | 1974 | 1 | 0.010 |
Why?
| | Leucine | 1 | 1994 | 116 | 0.010 |
Why?
| | Atrophy | 1 | 1994 | 199 | 0.010 |
Why?
| | Intercellular Junctions | 1 | 1994 | 35 | 0.010 |
Why?
| | Neuraminidase | 1 | 1974 | 27 | 0.010 |
Why?
| | Vibrio cholerae | 1 | 1974 | 14 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1994 | 334 | 0.010 |
Why?
| | Young Adult | 1 | 2011 | 14330 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 1999 | 740 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1997 | 1031 | 0.010 |
Why?
| | Genes, Reporter | 1 | 1994 | 275 | 0.010 |
Why?
| | Pregnancy | 1 | 1987 | 7230 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 1981 | 806 | 0.010 |
Why?
| | Chick Embryo | 1 | 1993 | 132 | 0.010 |
Why?
| | Recombination, Genetic | 1 | 1994 | 202 | 0.010 |
Why?
| | Immune System | 1 | 1994 | 181 | 0.010 |
Why?
| | DNA, Bacterial | 1 | 1993 | 319 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1993 | 327 | 0.010 |
Why?
| | Denervation | 1 | 1992 | 25 | 0.010 |
Why?
| | Adolescent | 1 | 2011 | 22557 | 0.010 |
Why?
| | Oxygen | 1 | 1997 | 997 | 0.010 |
Why?
| | Triiodothyronine | 1 | 1991 | 55 | 0.010 |
Why?
| | Sheep | 1 | 1974 | 870 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 194 | 0.010 |
Why?
| | Temperature | 1 | 1974 | 635 | 0.010 |
Why?
| | Hypothyroidism | 1 | 1991 | 68 | 0.010 |
Why?
| | Heart Valve Diseases | 1 | 1992 | 151 | 0.010 |
Why?
| | Injections | 1 | 1991 | 201 | 0.000 |
Why?
| | Orchiectomy | 1 | 1990 | 72 | 0.000 |
Why?
| | Plasmids | 1 | 1991 | 373 | 0.000 |
Why?
| | Hematocrit | 1 | 1990 | 108 | 0.000 |
Why?
| | Ovariectomy | 1 | 1990 | 164 | 0.000 |
Why?
| | DNA Probes | 1 | 1989 | 57 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1989 | 77 | 0.000 |
Why?
| | Chickens | 1 | 1989 | 169 | 0.000 |
Why?
| | Lactates | 1 | 1988 | 82 | 0.000 |
Why?
| | Lactic Acid | 1 | 1988 | 295 | 0.000 |
Why?
| | Testosterone | 1 | 1990 | 419 | 0.000 |
Why?
| | 6-Ketoprostaglandin F1 alpha | 1 | 1986 | 17 | 0.000 |
Why?
| | Child | 1 | 1986 | 22693 | 0.000 |
Why?
| | Kidney | 1 | 1993 | 1498 | 0.000 |
Why?
| | Lymphatic Metastasis | 1 | 1981 | 335 | 0.000 |
Why?
| | Hemagglutination | 1 | 1977 | 7 | 0.000 |
Why?
| | Mitogens | 1 | 1977 | 55 | 0.000 |
Why?
| | Antibody Formation | 1 | 1977 | 290 | 0.000 |
Why?
| | Lymphocytes | 1 | 1977 | 379 | 0.000 |
Why?
|
|
Buttrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|